US life expectancy stalls due to cardiovascular disease, not drug deaths

Publication Abstract

Mehta, Neil, Leah R. Abrams, and Mikko Myrskylä. Forthcoming. "US life expectancy stalls due to cardiovascular disease, not drug deaths." Proceedings of the National Academy of Sciences.

After decades of robust growth, the rise in US life expectancy stalled after 2010. Explanations for the stall have focused on rising drug-related deaths. Here we show that a stagnating decline in cardiovascular disease (CVD) mortality was the main culprit, outpacing and overshadowing the effects of all other causes of death. The CVD stagnation held back the increase of US life expectancy at age 25 y by 1.14 y in women and men, between 2010 and 2017. Rising drug-related deaths had a much smaller effect: 0.1 y in women and 0.4 y in men. Comparisons with other high-income countries reveal that the US CVD stagnation is unusually strong, contributing to a stark mortality divergence between the US and peer nations. Without the aid of CVD mortality declines, future US life expectancy gains must come from other causes-a monumental task given the enormity of earlier declines in CVD death rates. Reversal of the drug overdose epidemic will be beneficial, but insufficient for achieving pre-2010 pace of life expectancy growth.

10.1073/pnas.1920391117

Browse | Search | Next

PSC In The News

RSS Feed icon

Miller comments on local efforts to provide healthcare to vulnerable populations

Shaefer discusses Americans with tight financial resources have fewer options as they navigate coronavirus closures and layoffs in NYT

Mehta's research on life expectancy crisis in the USA: The opioid crisis is not the decisive factor

More News

Highlights

Data Scientist Job Open at PSC/PDHP

New Investigator Mentoring Program (PDHP) Applications Sought

More Highlights


Connect with PSC follow PSC on Twitter Like PSC on Facebook